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ously determine whether MAVS is involved in TLR3 sig-
naling.
Although much work is required to fully describe the
MAVS-dependent signaling pathways, the identification
of MAVS and its mitochondrial localization is a major
advance in our understanding of the intracellular detec-
tion of viral infection. The fact that mitochondria may
be important in innate immunity hints at the possibility
of a direct link between viral infection and the regula-
tion of apoptosis. In fact, preliminary studies by Seth et
al. show that knockdown of MAVS gene expression by
small interfering RNAs leads to an increase in apopto-
sis. Thus, MAVS could protect cells from apoptosis dur-
ing the early stages of viral infection, maximizing the
production of cytokines from the infected cell. In any
case, these exciting new findings highlight the central
part played by mitochondria in balancing the host im-
mune response and programmed cell death response
to virus and possibly to other pathogens.
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Note Added in Proof
While this preview was in press, a related article appeared online
(Kawai et al., 2005, Nat. Immunol., doi: 10.1038/ni1243). This article
also reports the identification of MAVS (which the authors named
IPS-1). Consistent with the studies featured here, IPS-1/MAVS is
required for RIG-1 and Mda5-dependent induction of IFN-b gene
expression. In addition, IPS-1/MAVS binds to RIG-1 and Mda5 as
well as to both RIP1 and FADD. Finally, overexpression of domi-
nant-negative FADD blocks IPS-1/MAVS-dependent expression of
an NF-κB reporter gene, thus providing evidence that RIP1 and
FADD mediate the activation of NF-κB through the RIG-1 pathway.
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Megalin is a member of the low-density lipoprotein
receptor-related protein (LRP) family. The plasma
membrane-anchored LRPs serve as receptors for a
wide variety of extracellular ligands, promoting their
entry into cells by endocytosis of the receptor-ligand
complex. In this issue of Cell, Hammes et al. (2005)
show that resistance (insensitivity) to sex steroid hor-
mones is encountered in animals lacking megalin.
These data provide important insights into an endo-
cytic mechanism for the uptake of sex steroids by
mammalian cells.
The first hint that megalin, the largest member of the
LRP family (Nykjaer and Willnow, 2002), may be impor-
tant in maintaining the endocrine (hormone) balance of
mammals came from the work of Nykjaer and col-
leagues (Nykjaer et al., 1999). They showed that mice
lacking megalin developed vitamin D deficiency and as
a result bone disease (vitamin D is required for main-
taining healthy bones). This defect was due to the in-
ability of the megalin-deficient luminal membrane of the
proximal renal tubular epithelial cell to recognize and
internalize the vitamin D precursor bound to its binding
protein. This internalization abnormality then led to
failed delivery of the vitamin D precursor to the mito-
chondrial enzyme that converts it to the active hor-
mone, 1,25 dihydroxyvitamin D.
Hammes et al. (2005) now report that the vitamin D
hormone pathway is not the only classical steroid hor-
mone pathway that is dependent, at least in part, on
megalin. They provide convincing evidence for a path-
way for sex steroid uptake in which a complex of the
serum sex hormone with its binding protein, the serum
sex hormone binding globulin (SHBG), becomes inter-
nalized by interacting with megalin. SHBG is equivalent
to the serum vitamin D binding protein for circulating
androgens and estrogens. The presence of megalin ap-
pears to be crucial for optimal internalization of sex ste-
roid hormones and for access of the hormone to its
cognate intracellular receptor in vitro. This appears to
be true in vivo, at least temporally, as female mice that
lack megalin show abnormalities in vaginal opening in
response to estrogen, and megalin-deficient male mice
exhibit defects in testicular descent in response to an-
drogens. Both conditions are specific sex steroid-depen-
dent events in the postnatal development of rodent geni-
talia. Simply increasing the amount of androgen in
pregnant mice did not rescue the embryonic genital de-
fects, indicating that free hormone was not able to
compensate for the lack of megalin. However, the fact
that megalin-deficient animals are not phenocopies of
mice lacking androgen or estrogen receptors suggests
that there must be megalin-independent pathways for
the entry of sex steroids into target cells expressing the
appropriate hormone receptor.
The classic dogma regarding sex steroid hormone
entry into target cells is the “free” hormone hypothesis
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648(see Figure 1, upper panel). This hypothesis states that,
by virtue of its small size and lipid solubility, only the
“free” steroid hormone, which has escaped the grasp
of its circulating serum binding protein, can traverse
the plasma membrane of target cells. Once inside the
cell, the steroid hormone must locate the intracellular
protein with which it needs to interact. For example,
the target protein for testosterone may be the androgen
receptor, or it may be the enzyme 5α-reductase for
which testosterone is the preferred substrate and dihy-
drotestosterone the product. The inability to efficiently
deliver androgen to its cognate receptor or testoster-
one to the 5α-reductase will result in incomplete andro-
genization of the host and a phenotype not dissimilar
from that exhibited by male mice deficient in megalin
(Griffin et al., 1982). However, as megalin-deficient ani-
mals are not completely resistant to androgens or
estrogens, this suggests that either “free” hormone is
somehow able to find its way to the androgen receptor
or estrogen receptor, or that there exist other plasma-
membrane receptors that promote the internalization of
the steroid hormone. It is also possible, as suggested
by Hammes et al. (2005) and others (reviewed by Men-
del, 1989), that both entry mechanisms (“free” and
“protein bound”) coexist in the same cell.
One could envisage three steps in the protein bound
entry mediated by megalin of estrogen and androgen
(either testosterone or dihydrotestosterone) into target
cells (see Figure 1, bottom panel). In the first step, the
circulating SHBG protein bearing its sex steroid cargo
interacts with megalin embedded in clathrin-coated
pits (Nagai et al., 2005) in the plasma membrane. The
next step is the formation of an endocytic vesicle,
which envelops the binding protein and its cargo bound
to megalin. Finally, there is dissociation of the binding
protein from its steroid ligand inside the vesicle, pre-
sumably through acidification of the vesicle lumen
(Gekle, 2005). If, as postulated by Hammes et al. (2005),
protein bound androgens and estrogens can enter the
cell by megalin-mediated endocytosis, how is it that
they escape the confines of the endocytic vesicle to
reach their intracellular destination? The “free” hor-
mone hypothesis holds that once dissociated from the
binding protein, the steroid diffuses through the vesicu-
lar membrane until it encounters its intracellular binding
targets. Alternatively, as is the case with low-density
lipoprotein (LDL)-cholesterol (Soccio and Breslow, 2004)
internalization, there is mounting evidence suggesting
the existence of trafficking intermediates (chaperones)
for the delivery of small, lipid-soluble, vitamin D sterol
and gonadal steroid hormones to specific intracellular
proteins, including receptors and metabolizing enzymes
(Adams et al., 2004). It is also possible that directed
vesicular transport of the intact complex containing
megalin bound to the sex steroid and its binding protein
(that results from targeted docking of the cytoplasmi-
cally exposed, carboxyl terminus of the megalin mole-
cule) is responsible for moving the steroid to such des-
tinations (R. Chun and J.S.A., unpublished data).
Regardless of the mechanism, the Hammes et al.
study and previous work force us to re-address an is-
sue of substantial practical importance in the field of
reproductive hormone biology. The issue is do mea-
surements of the “free” (protein unbound) fraction of
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Ligure 1. Possible Pathways for the Uptake of Sex Steroids by Tar-
et Cells that Contain Intracellular Steroid Receptors
Upper panel) The “free” hormone mode of entry. In this model,
teroids (pink) that are not bound to their cognate binding protein
SHBG, in the case of sex hormones, dark blue) diffuse across the
lasma membrane and then interact with their intracellular protein
argets: metabolizing enzymes (turquoise) or hormone receptors
orange). (Lower panel) The “bound” megalin-dependent mode of
teroid hormone entry (Hammes et al., 2005). SHBG and its sex
teroid hormone cargo bind to megalin (gray rod) concentrated in
lathrin-coated pits in the plasma membrane (step 1) (clathrin is
ot shown). The hormone-SHBG-megalin complex then is internal-
zed in endocytic vesicles (step 2). Megalin-mediated endocytosis
s followed by release of the hormone cargo from its binding protein
dark green), which may occur during vesicle acidification (step 3,
ale green). How the hormone, regardless of its route of internaliza-
ion, is localized to specific intracellular protein targets including
ognate sex steroid receptor proteins or metabolizing enzymes
such as, 5α-reductase or aromatase) remains unknown.otal hormone present in the plasma or serum of the
ost constitute the biologically relevant form of the
teroid that interacts with its intracellular receptor and
egulates hormone-directed transcription? Current esti-
ates are that 30% of American males in the 60- to
0-year-old age group and 70% of those in the 70- to
0-year-old age group have low serum bioavailable or
free’” testosterone levels (Hijazi and Cunningham,
005). If not at risk for androgen-promoted prostate or
ardiovascular disease, should we consider male hor-
one replacement in such men a treatment that en-
ances muscle mass, strength, mood, and libido and
reats osteopenia (low bone mass), osteoporosis, and
rectile dysfunction, if their “free” testosterone is low?
lthough this field requires substantial further research,
he results that Hammes et al. present here suggest that
e may need to re-examine clinical decisions based on
he extracellular concentration of “free” hormone.
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